A silent health crisis may be developing inside your body without any obvious warning signs. Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease ...

Dan Marino is opening up about his health — and offering reassurance to fans in the process. The NFL Hall of Famer, 64, gives ...

Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...

A Boehringer Ingelheim drug in development for weight loss now has data from a separate mid-stage clinical trial showing dramatic reductions across several measures of a fatty liver disease whose ...

Semaglutide, the popular weight loss and diabetes drug, now has the green light to treat moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). If you have the condition and are ...

Altimmune reports positive 48-week Phase 2b data for pemvidutide in MASH, showing fibrosis improvement, weight loss, and strong tolerability.

The MarketWatch News Department was not involved in the creation of this content. -- Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases ...

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week. The pill, called resmetirom, is ...

Positive results from the STAM mouse model in vivo study attributing Thykamine™ with anti-MASH and anti-fibrosis effects in liver Compelling results compared to Resmetirom, the first FDA approved drug ...

Imagine sitting in a doctor’s office and being told you have “non-alcoholic” liver disease. Before the doctor even finishes explaining what that means, your brain is already doing gymnastics trying to ...

MASH patients exhibit a higher spleen-to-liver stiffness ratio than ALD patients, indicating a presinusoidal component in portal hypertension. The study found that MASH patients have larger spleen ...

BAGSVÆRD, Denmark & PLAINSBORO, N.J., Nov. 10, 2025 /PRNewswire/ -- Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver ...